Reperfusion therapy

Reperfusion therapy has become so central to the modern treatment of acute myocardial infarction, that we are said to be in the reperfusion era.[1][2] Patients who present with suspected acute myocardial infarction and ST segment elevation (STEMI) or new bundle branch block on the 12 lead ECG are presumed to have an occlusive thrombosis in an epicardial coronary artery. They are therefore candidates for immediate reperfusion, either with thrombolytic therapy, percutaneous coronary intervention (PCI) or when these therapies are unsuccessful, bypass surgery.

Individuals without ST segment elevation are presumed to be experiencing either unstable angina (UA) or non-ST segment elevation myocardial infarction (NSTEMI). They receive many of the same initial therapies and are often stabilized with antiplatelet drugs and anticoagulated. If their condition remains (hemodynamically) stable, they can be offered either late coronary angiography with subsequent restoration of blood flow (revascularization), or non-invasive stress testing to determine if there is significant ischemia that would benefit from revascularization. If hemodynamic instability develops in individuals with NSTEMIs, they may undergo urgent coronary angiography and subsequent revascularization. The use of thrombolytic agents is contraindicated in this patient subset, however.[3]

The basis for this distinction in treatment regimens is that ST segment elevations on an ECG are typically due to complete occlusion of a coronary artery. On the other hand, in NSTEMIs there is typically a sudden narrowing of a coronary artery with preserved (but diminished) flow to the distal myocardium. Anticoagulation and antiplatelet agents are given to prevent the narrowed artery from occluding.

At least 10% of patients with STEMI don't develop myocardial necrosis (as evidenced by a rise in cardiac markers) and subsequent Q waves on EKG after reperfusion therapy. Such a successful restoration of flow to the infarct-related artery during an acute myocardial infarction is known as "aborting" the myocardial infarction. If treated within the hour, about 25% of STEMIs can be aborted.[4]

Contents

Thrombolytic therapy

Main article: Thrombolysis

Thrombolytic therapy is indicated for the treatment of STEMI if the drug can be administered within 12 hours of the onset of symptoms, the patient is eligible based on exclusion criteria, and primary PCI is not immediately available.[5] The effectiveness of thrombolytic therapy is highest in the first 2 hours. After 12 hours, the risk associated with thrombolytic therapy outweighs any benefit.[3][6] Because irreversible injury occurs within 2–4 hours of the infarction, there is a limited window of time available for reperfusion to work.

Thrombolytic drugs are contraindicated for the treatment of unstable angina and NSTEMI[3][7] and for the treatment of individuals with evidence of cardiogenic shock.[8]

Although no perfect thrombolytic agent exists, an ideal thrombolytic drug would lead to rapid reperfusion, have a high sustained patency rate, be specific for recent thrombi, be easily and rapidly administered, create a low risk for intra-cerebral and systemic bleeding, have no antigenicity, adverse hemodynamic effects, or clinically significant drug interactions, and be cost effective.[9] Currently available thrombolytic agents include streptokinase, urokinase, and alteplase (recombinant tissue plasminogen activator, rtPA). More recently, thrombolytic agents similar in structure to rtPA such as reteplase and tenecteplase have been used. These newer agents boast efficacy at least as well as rtPA with significantly easier administration. The thrombolytic agent used in a particular individual is based on institution preference and the age of the patient.

Depending on the thrombolytic agent being used, adjuvant anticoagulation with heparin or low molecular weight heparin may be of benefit.[10][11] With TPa and related agents (reteplase and tenecteplase), heparin is needed to maintain coronary artery patency (openness.) Because of the anticoagulant effect of fibrinogen depletion with streptokinase[12] and urokinase[13][14][15] treatment, it is less necessary there.[10]

Intracranial bleeding (ICB) and subsequent cerebrovascular accident (CVA) is a serious side effect of thrombolytic use. The risk of ICB is dependent on a number of factors, including a previous episode of intracranial bleed, age of the individual, and the thrombolytic regimen that is being used. In general, the risk of ICB due to thrombolytic use for the treatment of an acute myocardial infarction is between 0.5 and 1 percent.[10]

Thrombolytic therapy to abort a myocardial infarction is not always effective. The degree of effectiveness of a thrombolytic agent is dependent on the time since the myocardial infarction began, with the best results occurring if the thrombolytic agent is used within two hours of the onset of symptoms.[16][17] If the individual presents more than 12 hours after symptoms commenced, the risk of intracranial bleed are considered higher than the benefits of the thrombolytic agent.[18] Failure rates of thrombolytics can be as high as 20% or higher.[19] In cases of failure of the thrombolytic agent to open the infarct-related coronary artery, the patient is then either treated conservatively with anticoagulants and allowed to "complete the infarction" or percutaneous coronary intervention (PCI, see below) is then performed. Percutaneous coronary intervention in this setting is known as "rescue PCI" or "salvage PCI". Complications, particularly bleeding, are significantly higher with rescue PCI than with primary PCI due to the action of the thrombolytic agent.

Percutaneous coronary intervention

Main article: Percutaneous coronary intervention

The benefit of prompt, expertly performed primary percutaneous coronary intervention over thrombolytic therapy for acute ST elevation myocardial infarction is now well established.[20][21][22] When performed rapidly by an experienced team, primary PCI restores flow in the culprit artery in more than 95% of patients compared with the spontaneous recanalization rate of about 65%.[20] Logistic and economic obstacles seem to hinder a more widespread application of percutaneous coronary intervention (PCI) via cardiac catheterization,[23] although the feasibility of regionalized PCI for STEMI is currently being explored in the United States.[24] The use of percutaneous coronary intervention as a therapy to abort a myocardial infarction is known as primary PCI. The goal of primary PCI is to open the artery as soon as possible, and preferably within 90 minutes of the patient presenting to the emergency room. This time is referred to as the door-to-balloon time. Few hospitals can provide PCI within the 90 minute interval,[25] which prompted the American College of Cardiology (ACC) to launch a national Door to Balloon (D2B) Initiative in November 2006. Over 800 hospitals have joined the D2B Alliance as of March 16, 2007.[26]

One particularly successful implementation of a primary PCI protocol is in the Calgary Health Region under the auspices of the Libin Cardiovascular Institute of Alberta. Under this model, EMS teams responding to an emergency electronically transmit the ECG directly to a digital archiving system that allows emergency room physicians and/or cardiologists to immediately confirm the diagnosis. This in turn allows for redirection of the EMS teams to facilities prepped to conduct time-critical angioplasty, based on the ECG analysis. In an article published in the Canadian Medical Association Journal in June 2007, the Calgary implementation resulted in a median time to treatment of 62 minutes.[27]

The current guidelines in the United States restrict primary PCI to hospitals with available emergency bypass surgery as a backup,[5] but this is not the case in other parts of the world.[28]

Primary PCI involves performing a coronary angiogram to determine the anatomical location of the infarcting vessel, followed by balloon angioplasty (and frequently deployment of an intracoronary stent) of the thrombosed arterial segment. In some settings, an extraction catheter may be used to attempt to aspirate (remove) the thrombus prior to balloon angioplasty. While the use of intracoronary stents do not improve the short term outcomes in primary PCI, the use of stents is widespread because of the decreased rates of procedures to treat restenosis compared to balloon angioplasty.[29]

Adjuvant therapy during primary PCI includes intravenous heparin, aspirin, and clopidogrel. Glycoprotein IIb/IIIa inhibitors are often used in the setting of primary PCI to reduce the risk of ischemic complications during the procedure.[30][31] Due to the number of antiplatelet agents and anticoagulants used during primary PCI, the risk of bleeding associated with the procedure is higher than during an elective PCI.[32]

Coronary artery bypass surgery

Main article: Coronary artery bypass graft surgery

Emergency bypass surgery for the treatment of an acute myocardial infarction (MI) is less common than PCI or medical management. From 1995 to 2004, the percentage of people with cardiogenic shock treated with primary PCI rose from 27.4% to 54.4%, while the increase in CABG treatment was only from 2.1% to 3.2%.[33] Emergency coronary artery bypass graft surgery (CABG) is usually undertaken to simultaneously treat a mechanical complication, such as a ruptured papillary muscle, or a ventricular septal defect, with ensueing cardiogenic shock.[34] In uncomplicated MI, the mortality rate can be high when the surgery is performed immediately following the infarction.[35] If this option is entertained, the patient should be stabilized prior to surgery, with supportive interventions such as the use of an intra-aortic balloon pump.[36] In patients developing cardiogenic shock after a myocardial infarction, both PCI and CABG are satisfactory treatment options, with similar survival rates.[37][38]

Coronary artery bypass surgery involves an artery or vein from the patient being implanted to bypass narrowings or occlusions on the coronary arteries. Several arteries and veins can be used, however internal mammary artery grafts have demonstrated significantly better long-term patency rates than great saphenous vein grafts.[39] In patients with two or more coronary arteries affected, bypass surgery is associated with higher long-term survival rates compared to percutaneous interventions.[40] In patients with single vessel disease, surgery is comparably safe and effective, and may be a treatment option in selected cases.[41] Bypass surgery has higher costs initially, but becomes cost-effective in the long term.[42] A surgical bypass graft is more invasive initially but bears less risk of recurrent procedures (but these may be again minimally invasive).[41]

Reperfusion dysrhythmia

Accelerated idioventricular rhythm (AIVR) which looks like slow ventricular tachycardia is a sign of a successful reperfusion.[43] No specific treatment of this rhythm is needed as it rarely changes into a more serious rhythm.[44]

References

  1. ^ Lee KL, Woodlief LH, Topol EJ et al. (1995). "Predictors of 30-Day Mortality in the Era of Reperfusion for Acute Myocardial Infarction". Circulation 91 (6): 1659–1668. PMID 7882472. 
  2. ^ Stone GW, Grines CL, Browne KF et al. (1995). "Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trail". J Am Coll Cardiol 25 (22): 370–377. doi:10.1016/0735-1097(94)00367-Y. PMID 7829790. 
  3. ^ a b c "Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group." Lancet 1994; 343(8893): 311-22. PMID 7905143
  4. ^ Verheugt FW, Gersh BJ, Armstrong PW (2006). "Aborted myocardial infarction: a new target for reperfusion therapy". Eur Heart J 27 (8): 901–4. doi:10.1093/eurheartj/ehi829. PMID 16543251. 
  5. ^ a b Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr (2004). "ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)". J Am Coll Cardiol 44 (3): 671–719. doi:10.1016/j.jacc.2004.07.002. PMID 15358045. http://www.acc.org/qualityandscience/clinical/guidelines/stemi/Guideline1/index.htm. 
  6. ^ Boersma E, Maas AC, Deckers JW, Simoons ML (1996). "Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour". Lancet 348 (9030): 771–5. doi:10.1016/S0140-6736(96)02514-7. PMID 8813982. 
  7. ^ "Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia." Circulation 1994; 89 (4): 1545-56. PMID 8149520
  8. ^ Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. (1999). "Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock". N Engl J Med 341 (9): 625–34. doi:10.1056/NEJM199908263410901. PMID 10460813. 
  9. ^ White HD, Van , de Werf FJ (1998). "Thrombolysis for acute myocardial infarction.". Circulation 97 (16): 1632–46. PMID 9593569. 
  10. ^ a b c The GUSTO investigators (1993). "An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators". N Engl J Med 329 (10): 673–82. doi:10.1056/NEJM199309023291001. PMID 8204123. 
  11. ^ Sabatine MS, Morrow DA, Montalescot G, Dellborg M, Leiva-Pons JL, Keltai M, Murphy SA, McCabe CH, Gibson CM, Cannon CP, Antman EM, Braunwald E; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. (2005). "Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial". Circulation 112 (25): 3846–54. doi:10.1161/CIRCULATIONAHA.105.595397. PMID 16291601. 
  12. ^ Cowley MJ, Hastillo A, Vetrovec GW, Fisher LM, Garrett R, Hess ML. (1983). "Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency". Circulation 67 (5): 1031–8. PMID 6831667. 
  13. ^ Lourenco DM, Dosne AM, Kher A, Samama M. (1989). "Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro". Thromb Haemost 62 (3): 923–6. PMID 2556812. 
  14. ^ Van de Werf F, Vanhaecke J, de Geest H, Verstraete M, Collen D. (1986). "Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction". Circulation 74 (5): 1066–70. PMID 2429783. 
  15. ^ Bode C, Schoenermark S, Schuler G, Zimmermann R, Schwarz F, Kuebler W. (1988). "Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction". Am J Cardiol 61 (13): 971–4. doi:10.1016/0002-9149(88)90108-7. PMID 2452564. 
  16. ^ Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. (2000). "Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis" (PDF). JAMA 283 (20): 2686–92. doi:10.1001/jama.283.20.2686. PMID 10819952. http://jama.ama-assn.org/cgi/reprint/283/20/2686.pdf?ijkey=c72b289825a3fd6ace7545ef61cd70936485e7e1. 
  17. ^ Boersma E, Maas AC, Deckers JW, Simoons ML. (1996). "Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour". Lancet 348 (9030): 771–5. doi:10.1016/S0140-6736(96)02514-7. PMID 8813982. 
  18. ^ LATE trial intestigatos. (1993). "Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction". Lancet 342 (8874): 759–66. doi:10.1016/0140-6736(93)91538-W. PMID 8103874. 
  19. ^ Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, et al. (1987). "Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge". Circulation 76 (1): 142–54. PMID 3109764. 
  20. ^ a b Keeley EC, Boura JA, Grines CL. (2003). "Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials". Lancet 361 (9351): 13–20. doi:10.1016/S0140-6736(03)12113-7. PMID 12517460. 
  21. ^ Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, et al. (1993). "A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group". N Engl J Med 328 (10): 673–9. doi:10.1056/NEJM199303113281001. PMID 8433725. 
  22. ^ The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. (1997). "A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction". N Engl J Med 336 (23): 1621–8. doi:10.1056/NEJM199706053362301. PMID 9173270. 
  23. ^ Boersma E, The Primary Coronary Angioplasty vs. Thrombolysis Group (2006). "Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients". Eur Heart J 27 (7): 779–88. doi:10.1093/eurheartj/ehi810. PMID 16513663. 
  24. ^ Rokos IC, Larson DM, Henry TD et al. (2006). "Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks". Am Heart J 152 (4): 661–7. doi:10.1016/j.ahj.2006.06.001. PMID 16996830. 
  25. ^ Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, Roumanis SA, Curtis JP, Nallamothu BK et al. (2006). "Strategies for reducing the door-to-balloon time in acute myocardial infarction". N Engl J Med 355 (22): 2308–20. doi:10.1056/NEJMsa063117. PMID 17101617. 
  26. ^ "D2B: An Alliance for Quality". American College of Cardiology. 2006. http://d2b.acc.org/. Retrieved April 15, 2007. 
  27. ^ De Villiers JS, Anderson T, McMeekin JD, et al.. (2007). "Expedited transfer for primary percutaneous coronary intervention: a program evaluation". CMAJ 176 (13): 1833–8. doi:10.1503/cmaj.060902. PMC 1891117. PMID 17576980. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1891117. 
  28. ^ Aversano T et al.. (2002). "Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial". JAMA 287 (15): 1943–51. doi:10.1001/jama.287.15.1943. PMID 11960536. 
  29. ^ Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC. (1999). "Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group". N Engl J Med 341 (26): 1949–56. doi:10.1056/NEJM199912233412601. PMID 10607811. 
  30. ^ Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ. (1998). "Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators". Circulation 98 (8): 734–41. PMID 9727542. 
  31. ^ Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators. (2003). "Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial". Circulation 108 (11): 1316–23. doi:10.1161/01.CIR.0000087601.45803.86. PMID 12939213. 
  32. ^ Mukherjee, Debabrata (2006). 900 Questions: An Interventional Cardiology Board Review. Lippincott Williams & Wilkins. ISBN 0781773490. 
  33. ^ Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS (2005). "Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock". JAMA 294 (4): 448–54. doi:10.1001/jama.294.4.448. PMID 16046651. http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=16046651. 
  34. ^ Townsend, Courtney M.; Beauchamp D.R., Evers M.B., Mattox K.L. (2004). Sabiston Textbook of Surgery - The Biological Basis of Modern Surgical Practice. Philadelphia, Pennsylvania: Elsevier Saunders. pp. 1871. ISBN 0-7216-0409-9. http://www.elsevier.com/wps/find/bookdescription.cws_home/701163/description#description. 
  35. ^ Kaul TK, Fields BL, Riggins SL, Dacumos GC, Wyatt DA, Jones CR (1995). "Coronary artery bypass grafting within 30 days of an acute myocardial infarction". Ann. Thorac. Surg. 59 (5): 1169–76. doi:10.1016/0003-4975(95)00125-5. PMID 7733715. http://linkinghub.elsevier.com/retrieve/pii/0003497595001255. 
  36. ^ Creswell LL, Moulton MJ, Cox JL, Rosenbloom M (1995). "Revascularization after acute myocardial infarction". Ann. Thorac. Surg. 60 (1): 19–26. PMID 7598589. http://linkinghub.elsevier.com/retrieve/pii/000349759500351K. 
  37. ^ White HD, Assmann SF, Sanborn TA, et al. (2005). "Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial". Circulation 112 (13): 1992–2001. doi:10.1161/CIRCULATIONAHA.105.540948. PMID 16186436. http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=16186436. 
  38. ^ Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD; SHOCK Investigators. (2006). "Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction". JAMA 295 (21): 2511–5. doi:10.1001/jama.295.21.2511. PMC 1782030. PMID 16757723. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1782030. 
  39. ^ Raja SG, Haider Z, Ahmad M, Zaman H (2004). "Saphenous vein grafts: to use or not to use?". Heart Lung Circ 13 (4): 403–9. doi:10.1016/j.hlc.2004.04.004. PMID 16352226. http://linkinghub.elsevier.com/retrieve/pii/S1443-9506(04)00140-4. 
  40. ^ Hannan EL, Racz MJ, Walford G, et al. (2005). "Long-term outcomes of coronary-artery bypass grafting versus stent implantation". N. Engl. J. Med. 352 (21): 2174–83. doi:10.1056/NEJMoa040316. PMID 15917382. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15917382&promo=ONFLNS19. 
  41. ^ a b Bourassa MG (2000). "Clinical trials of coronary revascularization: coronary angioplasty vs. coronary bypass grafting". Curr. Opin. Cardiol. 15 (4): 281–6. doi:10.1097/00001573-200007000-00013. PMID 11139092. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0268-4705&volume=15&issue=4&spage=281. 
  42. ^ Hlatky MA, Boothroyd DB, Melsop KA, et al. (2004). "Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease". Circulation 110 (14): 1960–6. doi:10.1161/01.CIR.0000143379.26342.5C. PMID 15451795. http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=15451795. 
  43. ^ Osmancik PP, Stros P, Herman D (2008). "In-hospital arrhythmias in patients with acute myocardial infarction - the relation to the reperfusion strategy and their prognostic impact". Acute Card Care 10 (1): 15–25. doi:10.1080/17482940701474478. PMID 17924228. 
  44. ^ Dalzell JR, Jackson CE (April 2009). "When the rhythm makes the diagnosis". J Emerg Med. doi:10.1016/j.jemermed.2009.02.028. PMID 19345050.